Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899908 | 0.87 | MDM2 (0.37) | TSHR | |
| SCHEMBL1898635 | 0.86 | ELANE (0.37) | EPHX2 | |
| SCHEMBL1897598 | 0.83 | SLC6A3 (0.36) | TSHR | |
| SCHEMBL1900427 | 0.82 | TP53 (0.37) | EPHX2 | |
| SCHEMBL1897670 | 0.82 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL1899278 | 0.80 | EPHX2 (0.36) | EPHX2 | |
| SCHEMBL1899564 | 0.80 | MEN1 (0.34) | TSHR | |
| SCHEMBL1898143 | 0.80 | HSD11B1 (0.42) | EPHX2 | |
| SCHEMBL1901680 | 0.78 | MEN1 (0.34) | — | |
| SCHEMBL1896176 | 0.78 | HSD11B1 (0.44) | TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | claimed |
| EP-2322505-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-05-18 | — | — | EP | claimed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | claimed |
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2322505-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD3B1, CYP46A1 | TSHR 756/4885EPHX2 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.